The estimated Net Worth of Rudolf Kwan is at least 1.53 百万$ dollars as of 3 August 2022. Rudolf Kwan owns over 17,500 units of Athenex Inc stock worth over 59,062$ and over the last 7 years he sold ATNX stock worth over 0$. In addition, he makes 1,473,850$ as Chief Medical Officer at Athenex Inc.
Sign up
Rudolf Kwan ATNX stock SEC Form 4 insiders trading
Rudolf has made over 13 trades of the Athenex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 17,500 units of ATNX stock worth 3,500$ on 3 August 2022.
The largest trade he's ever made was exercising 24,000 units of Athenex Inc stock on 7 May 2021 worth over 109,200$. On average, Rudolf trades about 1,990 units every 32 days since 2017. As of 3 August 2022 he still owns at least 295,312 units of Athenex Inc stock.
You can see the complete history of Rudolf Kwan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rudolf Kwan biography
Dr. Rudolf Kwan serves as Chief Medical Officer of the Company. Dr. Kwan was engaged on a consultant basis. Dr. Kwan has over 20 years of experience in the pharmaceutical industry in global clinical development and operations. Before joining us, he served dual roles at Schering-Plough as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development (“CNS”). In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific for Schering-Plough. As Vice President of Global CNS he was responsible for the clinical development of all Schering-Plough’s central nervous system drugs, globally, where his achievements included overseeing development and execution of a bioequivalence registration strategy for a new formulation of Temodol for glioblastoma, which led to a simultaneous global registration. He also designed and executed multiple global development programs. He held similar positions at Chiron Corporation and was at Smith-Kline Beecham. Dr. Kwan obtained his medical degree (MBBS) from the University of Hong Kong, and received subsequent training at the University of Wales and is a member of the Royal College of Physicians in the United Kingdom.
What is the salary of Rudolf Kwan?
As the Chief Medical Officer of Athenex Inc, the total compensation of Rudolf Kwan at Athenex Inc is 1,473,850$. There are 1 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of 4,483,840$.
How old is Rudolf Kwan?
Rudolf Kwan is 67, he's been the Chief Medical Officer of Athenex Inc since 2014. There are 7 older and 10 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
What's Rudolf Kwan's mailing address?
Rudolf's mailing address filed with the SEC is C/O ATHENEX, INC.,, 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Insiders trading at Athenex Inc
Over the last 7 years, insiders at Athenex Inc have traded over 33,215,399$ worth of Athenex Inc stock and bought 5,920,005 units worth 73,651,360$ . The most active insiders traders include Advisors Llcperceptive Life...、Song Yi Zhang、Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of 10,843$. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth 125$.
What does Athenex Inc do?
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
What does Athenex Inc's logo look like?
Complete history of Rudolf Kwan stock trades at Athenex Inc
Athenex Inc executives and stock owners
Athenex Inc executives and other stock owners filed with the SEC include:
-
Johnson Lau,
Chief Executive Officer and Chairman of the Board -
Rudolf Kwan,
Chief Medical Officer -
Jeffrey Yordon,
Chief Operating Officer and President, Athenex Pharmaceutical Division -
Randoll Sze,
Chief Financial Officer -
Simon Pedder,
Chief Business and Strategy Officer - Proprietary Products -
Jeffrey M. Yordon,
COO & Pres of Athenex Pharmaceutical Division -
Dr. Rudolf Kwan M.D., M.B., B.S.,
Chief Medical Officer -
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
Chairman & CEO -
Benson Tsang,
Independent Director -
Stephanie Davis,
Independent Director -
Kim Campbell,
Lead Independent Director -
Jinn Wu,
Independent Director -
Jordan Kanfer,
Independent Director -
John Vierling,
Independent Director -
Manson Fok,
Director -
Robert Spiegel,
Director -
Daniel Lang,
Senior Director - Corporate Development, President - Axis Therapeutics Limited -
Tim McCarthy,
IR Contact Officer -
William Zuo,
President, China Division -
Dr. Wing-Kai Chan,
Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms -
John W. Matthei,
VP of HR -
Caileigh Dougherty,
Director of Investor Relations -
Michael Smolinski Ph.D.,
Chief Scientific Officer -
Steven J. Adams,
Interim Chief Accounting Officer -
Daniel Lang M.D.,
Sr. Director of Corp. Devel. -
Jacqueline Li,
Director of Corp. Devel. & Investor Relations -
Steven Rubis,
Sr. Director of Investor Relations -
Teresa Brophy Bair,
Gen. Counsel, Sr. VP of Admin. & Corp. Sec. -
Dr. Allen Barnett,
Co-Founder & Pres Emeritus -
James Zukin,
-
Michael D Cannon,
-
J Nick Riehle,
Chief Financial Officer -
Antony Leung,
-
Song Yi Zhang,
Director -
John Koh,
Director -
Advisors Llcperceptive Life...,
-
Sheldon Trainor Degirolamo,
Director -
Timothy De Vere Cook,
See Remarks -
Teresa Brophy Bair,
General Counsel, SVP Admin. -
Joe Annoni,
Chief Financial Officer -
Steven J. Adams,
Interim Chief Acct Officer -
Michael Smolinski,
Chief Scientific Officer